Aprocitentan Patent Expiration
Aprocitentan was first introduced by Idorsia Pharmaceuticals Ltd
Aprocitentan Patents
Given below is the list of patents protecting Aprocitentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tryvio | US11680058 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Jul 26, 2038 | Idorsia |
| Tryvio | US11787782 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | Mar 02, 2038 | Idorsia |
| Tryvio | US10919881 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Feb 26, 2038 | Idorsia |
| Tryvio | US12297189 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | Feb 26, 2038 | Idorsia |
| Tryvio | US11174247 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | Nov 06, 2037 | Idorsia |
| Tryvio | US8324232 | 4-pyrimidinesulfamide derivative | Sep 21, 2029 | Idorsia |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Aprocitentan's patents.
Latest Legal Activities on Aprocitentan's Patents
Given below is the list recent legal activities going on the following patents of Aprocitentan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 25 Aug, 2025 | US11680058 |
| Mail Certificate of Correction Memo | 25 Aug, 2025 | US11680058 |
| Certificate of Correction Memo | 21 Aug, 2025 | US11680058 |
| Second letter to regulating agency to determine regulatory review period | 19 Aug, 2025 | US8324232 |
| Information Disclosure Statement (IDS) Filed | 12 Aug, 2025 | US8324232 |
| Letter from FDA or Dept of Agriculture re PTE application | 12 Aug, 2025 | US8324232 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 May, 2025 | US11174247 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Aug, 2024 | US10919881 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 May, 2024 | US8324232 |
| Initial letter Re: PTE Application to regulating agency | 16 May, 2024 | US8324232 |
Aprocitentan's Family Patents
